MHE Question of the Week: Should the Medicare Cap Be Extended?
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
One of the most important provisions of the Inflation Reduction Act caps the out-of-pocket prescription drug costs of Medicare Beneficiaries. A $3,250 cap went into effect this year and will be lowered to $2,000 next year. But the limit only applies to those with Part D Medicare coverage, the part of Medicare that covers prescription drugs. President Joe Biden proposed extending the cap to health insurance sold on the commercial market in his State of the Union speech last week. Proponents of such limits say they make high-priced medications affordable, improving access to drugs that can reduce illness and lengthen lives. Detractors say limits will make premiums more expensive and also have long-term negative effects on the development of drugs.
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
Please pick the statement that most closely resembles your view
Should the Medicare $2,000 per-year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
Healthcare Leaders Warn GOP Plan Would Deeply Chip Away At Medicaid Access
May 12th 2025Their concerns come in response to the bill unveiled Sunday night by House Republicans that would tighten eligibility rules, create work requirements and freeze provider taxes under Medicaid—the federal-state program that insures nearly 80 million low-income Americans.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Lack of Social Support Top Barrier to Cell and Gene Therapy Access, Survey Finds
May 12th 2025Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration beyond academic medical centers into community and outpatient settings closer to patients' homes.
Read More
Survey Reveals Cancer Doctors Struggle to Keep Up as Treatments Advance Quickly
May 11th 2025A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.
Read More
